Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection

Pathology International

Volumn 52, Issue 7, 2002, Pages 442-450

  Hasegawa, Makoto ^a   Ohoka, Izuru ^a   Yamazaki, Kazuto ^a   Hanami, Kyota ^a   Sugano, Isamu ^a   Nagao, Toshitaka ^a   Asoh, Akira ^a   Wada, Nobuaki ^a   Nagao, Koichi ^a   Ishida, Yasuo ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Apoptosis; Esophageal squamous cell carcinoma; Human papillomavirus (HPV) infection; p21 WAF 1; p53

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA NUCLEOTIDYLEXOTRANSFERASE; PROTEIN P21; PROTEIN P53; VIRUS DNA;

APOPTOSIS; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE; CLINICAL ARTICLE; DNA DETERMINATION; ESOPHAGUS CARCINOMA; GENE DELETION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; NICK END LABELING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; SQUAMOUS CELL CARCINOMA; VERRUCA VULGARIS; VIRUS GENOME; WART VIRUS;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; DNA, VIRAL; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS;

EID: 0036371733     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2002.01373.x     Document Type: Article

References (42)

1. Papillomavirus infections - A major cause of human cancers
2. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
3. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
4. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
5. Tumour biology: p53, guardian of Rb
6. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells
7. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy
8. The pattern of p53 and p21WAF1/CIP1 immunoreactivity in non-Hodgkin's lymphomas predicts p53 gene status
9. Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas
10. Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China
11. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma
12. p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions
13. Rare association of human papillomavirus DNA with esophageal cancer in Japan
14. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
15. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
16. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas
17. Absence of p53 mutations in benign and pre-malignant male genital lesions with over-expressed p53 protein
18. The domain of p53 required for binding HPV 16, E6 is separable from the degradation domain
19. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation
20. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
21. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the 'hot spot' mutant phenotypes
22. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein
23. Mdm2 promotes the rapid degradation of p53
24. Molecular precursor lesions in oesophageal cancer
25. Multiple pathways control cell growth and transformation: Overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1
26. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD
27. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
28. The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells
29. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins
30. Human papillomavirus type 16, E6 increases the degradation rate of p53 in human keratinocytes
31. Cervical squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV
32. Expression of p53 protein related to the presence of human papillomavirus (HPV) DNA in genital carcinomas and precancer lesions
33. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient
34. The use of antigen retrieval for immunohistochemical detection of p53 over-expression in malignant and benign oral mucosa: A cautionary note
35. p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited!
36. p53 protein detected by immunohistochemical staining is not always mutant
37. Postthymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations
38. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations
39. Inhibition of p53 DNA binding by human papillomavirus E6 proteins
40. Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids
41. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma